Regeneron Pharmaceuticals’ (REGN) “Buy” Rating Reaffirmed at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reaffirmed by equities researchers at Truist Financial in a research note issued on Friday, Benzinga reports. They currently have a $1,200.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $1,135.00. Truist Financial’s price objective would indicate a potential upside of 9.78% from the company’s previous close.

A number of other research analysts also recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,077.91.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN opened at $1,093.14 on Friday. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 1-year low of $726.11 and a 1-year high of $1,106.16. The stock has a market capitalization of $120.45 billion, a P/E ratio of 32.29, a P/E/G ratio of 2.31 and a beta of 0.13. The business’s 50-day moving average price is $1,041.48 and its 200 day moving average price is $981.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Analysts expect that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth $932,571,000. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $339,594,000. Capital International Investors grew its holdings in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. First Trust Advisors LP increased its position in Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after acquiring an additional 195,902 shares in the last quarter. Finally, abrdn plc raised its stake in shares of Regeneron Pharmaceuticals by 552.8% in the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after acquiring an additional 186,215 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.